Sökning: onr:"swepub:oai:gup.ub.gu.se/252073" >
Prolonged-release f...
Prolonged-release fampridine and walking and balance in MS: Randomised controlled MOBILE trial
-
Hupperts, Raymond (författare)
-
- Lycke, Jan, 1956 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi,Institute of Neuroscience and Physiology
-
Short, Christine (författare)
-
visa fler...
-
Gasperini, Claudio (författare)
-
McNeill, Manjit (författare)
-
Medori, Rossella (författare)
-
Tofil-Kaluza, Agata (författare)
-
Hovenden, Maria (författare)
-
Mehta, Lahar R. (författare)
-
Elkins, Jacob (författare)
-
visa färre...
-
(creator_code:org_t)
- 2015-04-28
- 2016
- Engelska.
-
Ingår i: Multiple Sclerosis. - : SAGE Publications. - 1352-4585 .- 1477-0970. ; 22, s. 212-221
- Relaterad länk:
-
http://journals.sage...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- © SAGE Publications.Background: Mobility impairment is a common disability in MS and negatively impacts patients' lives. Objective: Evaluate the effect of prolonged-release (PR) fampridine (extended-release dalfampridine in the United States) on self-assessed walking disability, dynamic/static balance and safety in patients with MS. Methods: MOBILE was a randomised, double-blind, exploratory, placebo-controlled trial. Patients with progressive/relapsing-remitting MS and Expanded Disability Status Scale score of 4.0-7.0 were treated with PR-fampridine or placebo twice daily for 24 weeks. Efficacy endpoints included change from baseline in the 12-item MS Walking Scale (MSWS-12), Timed Up and Go (TUG) test and Berg Balance Scale (BBS). Results: 132 patients were randomised at 24 sites in six countries. PR-fampridine therapy resulted in greater median improvements from baseline in MSWS-12 score, TUG speed and BBS total score versus placebo over 24 weeks. A higher proportion of patients receiving PR-fampridine versus placebo experienced significant improvements at MSWS-12 improvement thresholds ≥7 (p = 0.0275), ≥8 (p = 0.0153) and ≥9 points (p = 0.0088) and TUG speed thresholds ≥10% (p = 0.0021) and ≥15% (p = 0.0262). PR-fampridine was well tolerated. Conclusions: PR-fampridine therapy resulted in early and sustained improvements in broad measures of walking and balance over six months.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Nyckelord
- balance
- Fampridine
- multiple sclerosis
- randomised clinical trial
- walking
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Hupperts, Raymon ...
-
Lycke, Jan, 1956
-
Short, Christine
-
Gasperini, Claud ...
-
McNeill, Manjit
-
Medori, Rossella
-
visa fler...
-
Tofil-Kaluza, Ag ...
-
Hovenden, Maria
-
Mehta, Lahar R.
-
Elkins, Jacob
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Neurovetenskaper
- Artiklar i publikationen
-
Multiple Scleros ...
- Av lärosätet
-
Göteborgs universitet